Talk to Dimerix Limited directly.
Sign up to their Investor Hub for direct access to the Dimerix Limited team, ask them questions, and see personal updates.
Dimerix is a clinical stage drug development company. The Company’s lead drug candidate DMX-200 is a chemokine receptor blocker. The Company’s clinical plan involves combining DMX-200 with Irbesartan, a angiotensin receptor blocker indicated for the treatment of hypertension and nephropathy in patients with kidney disease. DMX-200 is currently being tested in two Phase II clinical trials. Both trials are fully recruited and are due to report results in Q2 2020. The first study is targetting the rare chronic kidney disease FSGS and the second is targetting diabetic kidney disease. DMX-200 was discovered using the Company’s proprietary Receptor-HIT assay. Recently the Company announced that it had discovered its next pipeline candidate using the assay, DMX-700. DMX-700 will be investigated for the use in treating Chronic Obstructive Pulmonary Disease.
5/95 Hay St, Subiaco WA 6008, Australia
Earnings per share
Dividend per share